Drug Approval | October 05, 2023
Alembic received 6 USFDA approvals during Q2FY24
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
The investment will help the company meet soaring demand for user-friendly oral dosage form development and manufacturing
The products will be manufactured at the company's facility in Bengaluru
This approval has come from the company's finished dosage form manufacturing facility
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
Norgestrel and Ethinyl Estradiol Tablets USP (RLD Lo/Ovral-28) had an estimated annual sale of USD 34 million in the U.S. (IQVIA MAT Mar 2023)
The product basket increased to 1800 medicines and 285 Surgical Equipment
The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
The company has extended its full co-operation and support to the officials of the Income Tax Department
Subscribe To Our Newsletter & Stay Updated
